Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.16 USD
-0.13 (-5.68%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
Esperion Therapeutics, Inc. [ESPR]
Reports for Purchase
Showing records 61 - 80 ( 153 total )
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
We Heart a Significant Inflection Point; CLEAR Outcomes Trial Prepping to Report Topline Data in January; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
3Q22 Results; All Eyes On CLEAR Top-Line Readout Expected in 1Q23; Pipeline Updates at Upcoming R&D Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Expert Panel Recommends NEXLETOL As Important Adjunctive Therapy in ASCVD; Top-Line Phase 3 Readout 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
2Q22 Results; CLEARly the Focus Is on 1Q23 as Major Inflection Point
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
1Q22 Results; Revenue Growth Continues Across U.S. and E.U. Ahead of Key Inflection Point
Provider: H.C. Wainwright & Co., Inc.
Analyst: BRANCHETTI E
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
NEXLIZET''s Visibility on the Rise With CLEAR-ACS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
NEXLETOL Presentations at ACC.22 Continue to Showcase BDA''s Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Hitting the Achilles'' Heel Of Statins With Renovated Strategy; Initiating at Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department